

Cheyletiellosis

Darren Berger, DVM, DACVD
Iowa State University




▲ **FIGURE 1** A 10-year-old spayed Scottish terrier with cheyletiellosis demonstrating excessive, large scale formation. *Photo courtesy of J.O. Noxon, DVM, DACVIM, Iowa State University*

Cheyletiellosis, also known as *walking dandruff*, is an uncommon, contagious dermatosis caused by an infestation of the surface-dwelling *Cheyletiella* spp mite. Cheyletiellosis may occur in dogs (caused by *C yasguri*), cats (caused by *C blakei*), or rabbits (caused by *C parasitivorax*) and can also cause a transient infestation in humans that come in contact with pets carrying the mites. An increased incidence of mites may be observed in immunocompromised patients, in geographic regions where routine flea prevention is not practiced, or following exposure to high-volume housing situations (eg, catteries, breeding facilities).


Cheyletiella spp mites have a standard life cycle of egg, larva, nymph, and adult that can be completed in roughly 21 days. Mite life stages can be identified via direct examination of collected debris using a powerful magnifying lens or via microscopic examination of superficial skin scrapings, acetate tape impressions, and fecal flotation specimens. *Cheyletiella* spp mites are obligate parasites, as larvae, nymph, and adult male mites die soon after leaving the host; however, adult female mites are more robust and may survive up to 10 days off the host.¹

Clinical Signs


Clinical signs are highly variable, and subclinical carriers may be encountered. The most common clinical findings include mild-to-intense pruritus,




▲ **FIGURE 2** The dorsum of a 3-year-old neutered male cocker spaniel with mild erythema of the skin and lightly adherent scale formation secondary to *Cheyletiella* spp infestation



▲ **FIGURE 3** Two adult *Cheyletiella* spp mites identified on a superficial skin scraping sample. 4× objective




▲ **FIGURE 4** An adult *Cheyletiella* spp mite demonstrating characteristic hooks on the accessory mouthparts. 10× objective



▲ **FIGURE 5** A *Cheyletiella* spp egg found on a superficial skin scraping sample. 4× objective



Adult mites can be easily identified by the presence of prominent hooks on their accessory mouthparts.



▲ **FIGURE 6** A *Cheyletiella* spp egg loosely attached to hair by fibrillar stands. Photo courtesy of J.O. Noxon, DVM, DACVIM, Iowa State University

excessive scaling (particularly over the dorsum), and erythema (*Figures 1*, page 55, and *2*). In addition, cats may be presented with barbering alopecia or miliary dermatitis.¹

Diagnosis

Diagnosis is confirmed via visualization of the mite or ova, which may be difficult to recover from some patients with low-grade infestations. Adult mites can be easily identified by the presence of prominent hooks on their accessory mouthparts (*Figures 3* and *4*). *Cheyletiella* spp ova appear similar to louse eggs but are nonoperculated, smaller, and loosely attached to hairs (*Figures 5* and *6*).

Cheyletiellosis should be considered a differential diagnosis in patients with pruritus and excessive scaling; other ectoparasites, poor nutrition, intestinal parasitism, and primary seborrhea would also be considered differential diagnoses. In addition, *Cheyletiella* spp infestation should be eliminated as a potential cause in any patient presented for evaluation of a suspected allergic hypersensitivity (eg, atopy, food allergy).

Treatment

No licensed products are indicated specifically for the treatment of cheyletiellosis. Therapeutic protocol and medication selection primarily depend on the species of the animal affected and clinician preference. Most acaricidal flea preventive products and lime sulfur are effective, provided all in-contact animals are treated, the patient is treated for 6 weeks to disrupt the parasite's life cycle, and conventional environmental treatment—similar to what is recommended for flea infestation—is performed to prevent reinfestation. ■■■

Reference

1. Miller WH, Griffin CE, Campbell KL. Parasitic skin disease. In: Miller WH, Griffin CE, Campbell KL. *Muller and Kirk's Small Animal Dermatology*. 7th ed. St. Louis, MO: Elsevier Mosby; 2013:300-303.

30 mg/mL

BRIEF SUMMARY: Before using this product, please consult the full product insert for more information.

For oral use in dogs only

Appetite Stimulant

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: ENTYCE® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion.

Indication: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

Contraindications: ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.

Warnings: Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. **For use in dogs only**

Precautions: Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Adverse Reactions: Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTYCE (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting.

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-640-5500.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

NADA 141-457, Approved by FDA

US Patent: 6,673,929

US Patent: 9,700,591

Made in Canada



Manufactured for:
Aratana Therapeutics, Inc.
Leawood, KS 66211

ENTYCE is a trademark of Aratana Therapeutics, Inc.
© Aratana Therapeutics, Inc.

AT2-051-1

February 2018